Zobrazeno 1 - 10
of 464
pro vyhledávání: '"Paul, Lorigan"'
Autor:
Ann Tivey, Rebecca J. Lee, Alexandra Clipson, Steven M. Hill, Paul Lorigan, Dominic G. Rothwell, Caroline Dive, Florent Mouliere
Publikováno v:
Cell Reports Medicine, Vol 5, Iss 9, Pp 101736- (2024)
Summary: Treatments for cancer patients are becoming increasingly complex, and there is a growing desire from clinicians and patients for biomarkers that can account for this complexity to support informed decisions about clinical care. To achieve pr
Externí odkaz:
https://doaj.org/article/cbd19a1dac464bc5b87b5c1a4245e025
Autor:
Xue Bai, Ahmed Shaheen, Charlotte Grieco, Paolo D. d’Arienzo, Florentia Mina, Juliane A. Czapla, Aleigha R. Lawless, Eleonora Bongiovanni, Umberto Santaniello, Helena Zappi, Dominika Dulak, Andrew Williamson, Rebecca Lee, Avinash Gupta, Caili Li, Lu Si, Martina Ubaldi, Naoya Yamazaki, Dai Ogata, Rebecca Johnson, Benjamin C. Park, Seungyeon Jung, Gabriele Madonna, Juliane Hochherz, Yoshiyasu Umeda, Yasuhiro Nakamura, Christoffer Gebhardt, Lucia Festino, Mariaelena Capone, Paolo Antonio Ascierto, Douglas B. Johnson, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies, Kenjiro Namikawa, Mario Mandala, Jun Guo, Paul Lorigan, Yana G. Najjar, Andrew Haydon, Pietro Quaglino, Genevieve M. Boland, Ryan J. Sullivan, Andrew J.S. Furness, Ruth Plummer, Keith T. Flaherty
Publikováno v:
EClinicalMedicine, Vol 71, Iss , Pp 102564- (2024)
Externí odkaz:
https://doaj.org/article/377d8aad4882472db54c2cd4b6fbb9b1
Autor:
Domenico Mallardo, Rachel Woodford, Alexander M. Menzies, Lisa Zimmer, Andrew williamson, Egle Ramelyte, Florentia Dimitriou, Alexandre Wicky, Roslyn Wallace, Mario Mallardo, Alessio Cortellini, Alfredo Budillon, Victoria Atkinson, Shahneen Sandhu, Michielin Olivier, Reinhard Dummer, Paul Lorigan, Dirk Schadendorf, Georgina V. Long, Ester Simeone, Paolo A. Ascierto
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-11 (2023)
Abstract Background The combination of nivolumab + relatlimab is superior to nivolumab alone in the treatment of naive patients and has activity in PD-1 refractory melanoma. We had previously observed a reduced expression of LAG3 in melanoma tissue f
Externí odkaz:
https://doaj.org/article/f9c9d70fb3694e94a830225a5081faab
Autor:
Chun Wai Wong, Christos Evangelou, Kieran N. Sefton, Rotem Leshem, Wei Zhang, Vishaka Gopalan, Sorayut Chattrakarn, Macarena Lucia Fernandez Carro, Erez Uzuner, Holly Mole, Daniel J. Wilcock, Michael P. Smith, Kleita Sergiou, Brian A. Telfer, Dervla T. Isaac, Chang Liu, Nicholas R. Perl, Kerrie Marie, Paul Lorigan, Kaye J. Williams, Patricia E. Rao, Raghavendar T. Nagaraju, Mario Niepel, Adam F. L. Hurlstone
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-21 (2023)
Abstract Resistance mechanisms to immune checkpoint blockade therapy (ICBT) limit its response duration and magnitude. Paradoxically, Interferon γ (IFNγ), a key cytokine for cellular immunity, can promote ICBT resistance. Using syngeneic mouse tumo
Externí odkaz:
https://doaj.org/article/93f86ebcf5e046d68cb9b2272850303f
Autor:
Xue Bai, Ahmed Shaheen, Charlotte Grieco, Paolo D. d’Arienzo, Florentia Mina, Juliane A. Czapla, Aleigha R. Lawless, Eleonora Bongiovanni, Umberto Santaniello, Helena Zappi, Dominika Dulak, Andrew Williamson, Rebecca Lee, Avinash Gupta, Caili Li, Lu Si, Martina Ubaldi, Naoya Yamazaki, Dai Ogata, Rebecca Johnson, Benjamin C. Park, Seungyeon Jung, Gabriele Madonna, Juliane Hochherz, Yoshiyasu Umeda, Yasuhiro Nakamura, Christoffer Gebhardt, Lucia Festino, Mariaelena Capone, Paolo Antonio Ascierto, Douglas B. Johnson, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies, Kenjiro Namikawa, Mario Mandala, Jun Guo, Paul Lorigan, Yana G. Najjar, Andrew Haydon, Pietro Quaglino, Genevieve M. Boland, Ryan J. Sullivan, Andrew J.S. Furness, Ruth Plummer, Keith T. Flaherty
Publikováno v:
EClinicalMedicine, Vol 65, Iss , Pp 102290- (2023)
Summary: Background: Both dabrafenib/trametinib (D/T) and anti-PD-1 monotherapy (PD-1) are approved adjuvant therapies for patients with stage III BRAF V600-mutant melanoma. However, there is still a lack of head-to-head comparative data. We aimed to
Externí odkaz:
https://doaj.org/article/43eb9c43eb9a4af8ab0b21da71b61e89
Autor:
Alessia Visconti, Niccolò Rossi, Helena Deriš, Karla A Lee, Maja Hanić, Irena Trbojević-Akmačić, Andrew M. Thomas, Laura A. Bolte, Johannes R. Björk, Jahlisa S. Hooiveld-Noeken, Ruth Board, Mark Harland, Julia Newton-Bishop, Mark Harries, Joseph J. Sacco, Paul Lorigan, Heather M. Shaw, Elisabeth G.E. de Vries, Rudolf S.N. Fehrmann, Rinse K. Weersma, Tim D. Spector, Paul Nathan, Geke A. P. Hospers, Peter Sasieni, Veronique Bataille, Gordan Lauc, Mario Falchi
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-12 (2023)
Abstract Background Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of melanoma and other cancers. However, no reliable biomarker of survival or response has entered the clinic to identify those patients with melanoma who are mo
Externí odkaz:
https://doaj.org/article/50b511b7f9af46e6993f096da9d33865
Publikováno v:
EJC Skin Cancer, Vol 1, Iss , Pp 100001- (2023)
Externí odkaz:
https://doaj.org/article/251815d96de844cab664eee4c1960763
Publikováno v:
Endocrine Oncology, Vol 2, Iss 1, Pp K5-K9 (2023)
Short synacthen tests (SST) are frequently used for assessing adrenocorticotropin hormone (ACTH) deficiency. In this study, we present the case of a 53-year-old man receiving immunotherapy for metastatic melanoma, who subsequently developed immune ch
Externí odkaz:
https://doaj.org/article/1b3c4fcb0c174b04ba6a75cc915f79f5
Autor:
Niccolò Rossi, Karla A. Lee, Maria V. Bermudez, Alessia Visconti, Andrew Maltez Thomas, Laura A. Bolte, Johannes R. Björk, Laura Kist de Ruijter, Julia Newton-Bishop, Mark Harland, Heather M. Shaw, Mark Harries, Joseph Sacco, Ruth Board, Paul Lorigan, Elisabeth G.E. de Vries, Nicola Segata, Leonie Taams, Sophie Papa, Tim D. Spector, Paul Nathan, Rinse K. Weersma, Geke A.P. Hospers, Rudolf S.N. Fehrmann, Veronique Bataille, Mario Falchi
Publikováno v:
EBioMedicine, Vol 83, Iss , Pp 104235- (2022)
Summary: Background: Inflammation can modulate tumour growth and progression, and influence clinical response to treatment. We investigated the potential of circulating inflammatory proteins for response stratification of immune checkpoint inhibitor
Externí odkaz:
https://doaj.org/article/2653e1f206bf4483825a0683e7b29ab7
Autor:
Sara Valpione, Piyushkumar A. Mundra, Elena Galvani, Luca G. Campana, Paul Lorigan, Francesco De Rosa, Avinash Gupta, John Weightman, Sarah Mills, Nathalie Dhomen, Richard Marais
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-8 (2021)
Precision medicine needs prognostic markers to select the patients that will benefit more from targeted therapy. Authors show here that high level of baseline T cell receptor diversity is an indicator of favourable prognosis in multiple cancer types,
Externí odkaz:
https://doaj.org/article/5580ae6b92b14a67a7ff151b6081830b